Kincell Bio, a Research Triangle Park, NC- and Gainesville, FL-based contract development and manufacturing organization (CDMO), raised $22M in funding.
The round was led by NewSpring Capital through its dedicated healthcare strategy, NewSpring Healthcare, with participation from existing investors Kineticos Life Sciences.
The company intends to use the funds to accelerate its expansion of its cGMP capabilities, enhance its process development services, and support the development of solutions used to emerging cell therapy companies.
Led by Mark R. Bamforth, CEO, Kincell Bio is a contract development and manufacturing organization (CDMO) with the streamlining CMC development, applying expertise in analytical and processing development and GMP manufacturing to test and release from early clinical to pivotal studies and product launch. It is focused on supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programs, as well as developing expertise in stem cell products and iPSCs.
Its platform offers clients a personalized, responsive, and expert-driven approach to process development and manufacturing from early clinical to pivotal supply and commercial launch, ensuring rapid timelines without compromising on quality.
As part of this funding, Pete Buzy, former President and CEO of Catalent Cell and Gene Therapy, has been appointed to Kincell Bio’s Board of Directors.
FinSMEs
15/05/2025